Bioavailability and activity of phytosome complexes from botanical polyphenols: The silymarin, curcumin, green tea, and grape seed extracts

Alternative Medicine Review

Volumn 14, Issue 3, 2009, Pages 226-246

  Kidd, Parris M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; CURCUMIN; DISTEAROYLPHOSPHATIDYLCHOLINE; EPICATECHIN 3 GALLATE; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN 3 (3' METHYL)GALLATE; EPIGALLOCATECHIN GALLATE; GALLOCATECHIN 3 GALLATE; GLUTATHIONE; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; GREENSELECT; LEUCOSELECT; LIPOSOME; MERIVA; PLACEBO; SILIBININ; SILIPHOS; SILYMARIN; SULINDAC; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALCOHOL LIVER CIRRHOSIS; ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ASTHMA; BILIARY TRACT DISEASE; BLADDER CANCER; BLADDER DISEASE; BLADDER DYSPLASIA; BOWEN DISEASE; BRAIN EDEMA; BRAIN INJURY; BREAST CANCER; BRONCHUS HYPERREACTIVITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COGNITION; COLON CANCER; COUGHING; CYSTIC FIBROSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM INFLAMMATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DUODENUM CANCER; DYSPLASIA; ENTERITIS; ESOPHAGUS CANCER; EYE INFLAMMATION; FOLLICULAR LYMPHOMA; HEART MUSCLE ISCHEMIA; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; INTESTINE TUMOR; INTRAOCULAR HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOPLAKIA; LIPID OXIDATION; LIVER DISEASE; LIVER PROTECTION; LUNG CANCER; METAPLASIA; MOLECULAR IMAGING; MOUTH CANCER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PANCREATITIS; PARKINSON DISEASE; PAW EDEMA; POSTOPERATIVE INFLAMMATION; PRECANCER; PROSTATE CANCER; PROSTATE CARCINOMA; RECTUM CANCER; REPERFUSION INJURY; REVIEW; RHINORRHEA; SILYBUM MARIANUM; SINGLE DRUG DOSE; SINUSITIS; SKIN CANCER; SKIN DISEASE; SOLID TUMOR; SPRAIN; STOMACH CANCER; STOMACH METAPLASIA; STROKE; TOOTH DISEASE; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS HEPATITIS; WEIGHT REDUCTION; WOUND;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; CURCUMIN; FREE RADICAL SCAVENGERS; GRAPE SEED EXTRACT; HUMANS; MILK THISTLE; OXIDATIVE STRESS; PHYTOTHERAPY; PROTECTIVE AGENTS; SILYMARIN; TEA;

EID: 70350068120     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727-747.
2. Bombardelli E, Curri SB, Della Loggia R, et al. Complexes between phospholipids and vegetal derivatives of biological interest. Fitoterapia 1989;60:1-9.
3. www.indena.com/pdf/ephytosome.pdf [Accessed June 20, 2009]
4. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybinphosphatidylcholine complex (Siliphos®). Altern Med Rev 2005;10:193-203. (Pubitemid 41384033)
5. Pietta P, Simonetti P, Gardana C, et al. Relationship between rate and extent of catechin absorption and plasma antioxidant status. Biochem Mol Biol Int 1998;46:895-903. (Pubitemid 29004600)
6. Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007;60:171-177.
7. Indena SpA. Human pharmacokinetic study with curcumin. Unpublished.
8. Kidd PM. Phosphatidylcholine. In: Czap K, Miller AL, Head KA, et al, eds. Alternative Medicine Review Monographs Volume One. Dover, ID: Thorne Research, Inc.; 2002:310-315.
9. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th ed. New York, NY: Garland Science; 2002.
10. Hulbert AJ, Else PL. Membranes and the setting of energy demand. J Exp Biol 2005;208:1593-1599.
11. Malandrino S, Pifferi G. IdB-1016. Drugs Future 1990;15:226-227.
12. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-338.
13. Kidd PM. Glutathione. In: Czap K, Miller AL, Head KA, et al, eds. Alternative Medicine Review Monographs Volume One. Dover, ID: Thorne Research, Inc.; 2002:184-192.
14. Bares JM, Berger J, Nelson JE, et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol 2008;42:937-944.
15. Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715-757. (Pubitemid 35428791)
16. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964-968.
17. Schandalik R, Perucca E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp Clin Res 1994;20:37-42. (Pubitemid 24138770)
18. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005;12:559-567. (Pubitemid 41532486)
19. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504. (Pubitemid 46157708)
20. Marena C, Lampertico M. Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders. Planta Med 1991;57:A124-A125.
21. Marcelli R, Bizzoni P, Conte D, et al. Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res 1992;1:131-135.
22. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993;31:456-460. (Pubitemid 23262277)
23. Moscarella S, Giusti A, Marra F, et al. Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res 1993;53:98-102. (Pubitemid 23119453)
24. Vailati A, Aristia L, Sozze E, et al. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;94:219-228. (Pubitemid 23245298)
25. Buzzelli G, Moscarella S, Barbagli S, et al. Therapeutic effect of silipide in patients with chronic hepatitis C non-responders (NRs) to interferon (IFN) treatment. J Hepatol 1994;21:17.
26. Busby A, La Grange L, Edwards J, King J. The use of a silymarin/phospholipid compound as a fetoprotectant from ethanol-induced behavioral deficits. J Herb Pharmacother 2002;2:39-47. (Pubitemid 34196148)
27. Tedesco D, Steidler S, Galletti S, et al. Efficacy of silymarin-phospholipid complex in reducing the toxicity of aflatoxin B1 in broiler chicks. Poult Sci 2004;83:1839-1843. (Pubitemid 40669932)
28. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-146. (Pubitemid 46020872)
29. Sarkar FH, Li Y, Wang Z, Kong D. NF-kappa B signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008;27:293-319.
30. Manna SK, Mudkopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappaB, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:6800-6809.
31. www.clinicaltrials.gov/ct2/results?term=silybin; www.clinicaltrials.gov/ ct2/results?term=silymarin; www.clinicaltrials.gov/ct2/results?term=siliphos [Accessed July 1, 2009]
32. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008;269:352-362.
33. www.clinicaltrials.gov/ct2/show/NCT00055718?term=silymarin&rank=5; www.cancer.gov/clinicaltrials/ft-CPMC-IRB-14117 [Accessed July 1, 2009]
34. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
35. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008;10:511-545.
36. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-153.
37. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992;36:273-275. (Pubitemid 23031285)
38. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661. (Pubitemid 351348146)
39. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129:231-234. (Pubitemid 30072641)
40. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-1652.
41. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005;14:120-125. (Pubitemid 40165291)
42. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270:24995-25000.
43. Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991;51:813-819.
44. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007;595:127-148.
45. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008;326:196-208.
46. Kidd PM. Integrated brain restoration after ischemic stroke - medical management, risk factors, nutrients, and other interventions for managing inflammation and enhancing brain plasticity. Altern Med Rev 2009;44:14-35.
47. Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 2008;13:85-115.
48. Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol 1997;17:3406-3413.
49. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008;28:110-113.
50. Ringman J, Cummings J. Pilot Alzheimer's disease curcumin clinical trial. University of California Los Angeles; 2008: unpublished.
51. Fiala M, Liu PT, Espinosa-Jeffrey A, et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A 2007;104:12849-12854. (Pubitemid 47255243)
52. Zhang L, Fiala M, Cashman J, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2006;10:1-7. (Pubitemid 44401358)
53. Ng TP, Chiam PC, Lee T, et al. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006;164:898-906. (Pubitemid 44627275)
54. Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 2008;52:1040-1061.
55. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995;95:221-225.
56. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
57. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-4499.
58. www.clinicaltrials.gov/ct2/results?term=curcumin [Accessed July 3, 2009]
59. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008;17:1411-1417.
60. Coyle CH, Philips BJ, Morrisroe SN, et al. Antioxidant effects of green tea and its polyphenols on bladder cells. Life Sci 2008;83:12-18.
61. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 2008;138:1548S-1553S.
62. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 2005;14:46-60. (Pubitemid 40868983)
63. Nagao T, Meguro S, Hase T, et al. A catechin-rich beverage improves obesity and blood glucose control in patients with Type 2 diabetes. Obesity (Silver Spring) 2009;17:310-317.
64. Di Pierro F, Menghi AB, Barreca A, et al. Greenselect® phytosome as an adjunct to a low-calorie diet for treatment of obesity: a clinical trial. Altern Med Rev 2009;14:154-160.
65. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006;6:389-406.
66. Khan N, Afaq F, Saleem M, et al. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-2505.
67. Zhao B, Guo Q, Xin W. Free radical scavenging by green tea polyphenols. Methods Enzymol 2001;335:217-231. (Pubitemid 32507240)
68. Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. Curr Med Chem 2008;15:1840-1850.
69. Wang CZ, Mehendale SR, Yuan CS. Commonly used antioxidant botanicals: active constituents and their potential role in cardiovascular illness. Am J Chin Med 2007;35:543-558.
70. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res 1992;52:4050-4052.
71. Chou FP, Chu YC, Hsu JD, et al. Specific induction of glutathione S-transferase GSTM2 subunit expression by epigallocatechin gallate in rat liver. Biochem Pharmacol 2000;60:643-650.
72. Luo H, Tang L, Tang M, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006;27:262-268. (Pubitemid 43159878)
73. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci 2007;81:519-533.
74. Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 2009;25:147-154.
75. Krahwinkel T, Willershausen B. The effect of sugar-free green tea chew candies on the degree of inflammation of the gingiva. Eur J Med Res 2000;5:463-467.
76. Sakanaka S, Okubo T, Akachi S, et al. In: Yamamoto T, Juneja L, eds. Chemistry and Applications of Green Tea. New York, NY: CRC Press; 1997:145-149.
77. Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 2006;78:2073-2080.
78. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255-1265. (Pubitemid 44394897)
79. Kim W, Jeong MH, Cho SH, et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 2006;70:1052-1057. (Pubitemid 44161745)
80. Widlansky ME, Hamburg NM, Anter E, et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary heart disease. J Am Coll Nutr 2007;26:95-102. (Pubitemid 46911252)
81. Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol 2005;56:51-67. (Pubitemid 44922295)
82. Neuhaus T, Pabst S, Stier S, et al. Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3-gallate. Eur J Pharmacol 2004;483:223-227. (Pubitemid 38068403)
83. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002;155:732-738. (Pubitemid 34297653)
84. Tan EK, Tan C, Fook-Chong SM, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 2003;216:163-167. (Pubitemid 37376408)
85. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 2006;23:55-64.
86. Levites Y, Weinreb O, Maor G, et al. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-1082. (Pubitemid 32823156)
87. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing, and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-873. (Pubitemid 39482155)
88. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechin-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 2003;31:572-579. (Pubitemid 36444166)
89. Lee H, Bae JH, Lee SR. Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils. J Neurosci Res 2004;77:892-900. (Pubitemid 39187072)
90. Sutherland BA, Shaw OM, Clarkson AN, et al. Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 2005;19:258-260.
91. Kim SY, Ahn BH, Kim J, et al. Phospholipase C, protein kinase C, Ca2+/calmodulin-dependent protein kinase II, and redox state are involved in epigallocatechin gallate-induced phospholipase D activation in human astroglioma cells. Eur J Biochem 2004;271:3470-3480. (Pubitemid 39215337)
92. Kumazawa S, Kajiya K, Naito A, et al. Direct evidence of interaction of a green tea polyphenol, epigallocatechin gallate, with lipid bilayers by solid-state Nuclear Magnetic Resonance. Biosci Biotechnol Biochem 2004;68:1743-1747. (Pubitemid 39260305)
93. Choi YT, Jung CH, Lee SR, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001;70:603-614.
94. Shurkin J. Alternative ideas about Alzheimer's. Sci Am Mind 2009;July-Aug:10-11.
95. Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 2002;277:30574-30580. (Pubitemid 34970751)
96. Lee SY, Kim CY, Lee JJ, et al. Effects of delayed administration of (-)-epigallocatechin gallate, a green tea polyphenol on the changes in polyamine levels and neuronal damage after transient forebrain ischemia in gerbils. Brain Res Bull 2003;61:399-406.
97. Suganuma M, Okabe S, Oniyama M, et al. Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998;19:1771-1776. (Pubitemid 28476352)
98. Ahmad N, Feyes DK, Nieminen AL, et al. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881-1886. (Pubitemid 28009824)
99. Ahn WS, Yoo J, Huh SW, et al. Protective effects of green tea extract (Polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003;12:383-390. (Pubitemid 37338812)
100. Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-1446. (Pubitemid 36297774)
101. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999;125:589-597. (Pubitemid 29502339)
102. Suganuma M, Ohkura Y, Okabe S, Fujiki H. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol 2001;127:69-72. (Pubitemid 32128517)
103. Dashwood RH. Frontiers in polyphenols and cancer prevention. J Nutr 2007;137:267S-269S.
104. Wang JS, Luo H, Wang P, et al. Validation of green tea polyphenol biomarkers in a Phase II human intervention trial. Food Chem Toxicol 2008;46:232-240. (Pubitemid 350235769)
105. Simonetti P, Pietta PG, Brusamolino A, et al. Antioxidant activity of green tea: "in vivo" study. 16th International Congress of Nutrition; Montreal, Canada: July/August 1997.
106. Auvichayapat P, Prapochanung M, Tunkamnerdthai O, et al. Effectiveness of green tea on weight reduction in obese Thais: a randomized, controlled trial. Physiol Behav 2008;93:486-491. (Pubitemid 351208430)
107. Donovan JL, Manach C, Rios L, et al. Procyanidins are not bioavailable in rats fed a single meal containing a grapeseed extract or the procyanidin dimer B3. Br J Nutr 2002;87:299-306. (Pubitemid 34441169)
108. www.indena.it/pdf/leucoselect.pdf [Accessed June 5, 2009]
109. Maffei Facino R, Carini M, Aldini G, et al. Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung 1994;44:592-601. (Pubitemid 24179881)
110. Maffei Facino R, Carini M, Aldini G, et al. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 1996;62:495-502. (Pubitemid 27006681)
111. Carini M, Stefani R, Aldini G, et al. Procyanidins from Vitis vinifera seeds inhibit the respiratory burst of activated human neutrophils after lysosomal enzyme release. Planta Med 2001;67:714-717. (Pubitemid 33044476)
112. Aldini G, Carini M, Piccoli A, et al. Procyanidins from grape seeds protect endothelial cells from peroxynitrite damage and enhance endothelium-dependent relaxation in human artery: new evidences for cardioprotection. Life Sci 2003;73:2883-2898. (Pubitemid 37153361)
113. Maffei Facino R, Carini M, Aldini G, et al. Sparing effect of procyanidins from Vitis vinifera on vitamin E: in vitro studies. Planta Med 1998;64:343-347. (Pubitemid 28234273)
114. Simonetti P, Ciappellano S, Gardana C, et al. Procyanidins from Vitis vinifera seeds: in vivo effects on oxidative stress. J Agric Food Chem 2002;50:6217-6221. (Pubitemid 35155360)
115. Ursini F, Zamburlini A, Cazzolato G, et al. Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Free Radic Biol Med 1998;25:250-252. (Pubitemid 28293161)
116. Natella F, Belelli F, Gentili V, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. J Agric Food Chem 2002;50:7720-7725. (Pubitemid 35453739)
117. Vigna GB, Costantini F, Aldini G, et al. Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. Metabolism 2003;52:1250-1257. (Pubitemid 37351091)
118. Sharma SD, Meeran SM, Katiyar SK. Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-kappaB signaling in in vivo SKH-1 hairless mice. Mol Cancer Ther 2007;6:995-1005.
119. Katiyar SK. Grape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune system. Mol Nutr Food Res 2008;52:S71-S76.
120. Nandakumar V, Singh T, Katiyar SK. Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett 2008;269:378-387.